The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001-O007)
-
November 5, 2025
-
0 min
Clinical Scorecard: NSAIDs: A Simple Therapy for Managing Ghosal Hematodiaphyseal Dysplasia
At a Glance
| Category | Detail |
|---|---|
| Condition | Ghosal hematodiaphyseal dysplasia (GHD), a rare autosomal recessive bone marrow failure disorder |
| Key Mechanisms | Biallelic TBXAS1 mutations disrupt thromboxane A2 synthase1 causing severe anemia and diaphyseal cortical hypertrophy |
| Target Population | Patients with hypoproliferative normocytic anemia, thrombocytopenia, and bone anomalies consistent with GHD |
| Care Setting | Specialized hematology and bone marrow failure centers with genetic testing capabilities |
Key Highlights
- NSAIDs targeting COX1 and COX2 provide effective treatment for hematologic symptoms in GHD with minimal iatrogenic effects compared to corticosteroids
- All patients treated with NSAIDs achieved hemoglobin and platelet responses within a median of 3 and 2 months respectively
- Diagnosis is supported by bone marrow biopsy showing severe hypoplasia and imaging revealing diaphyseal cortical hypertrophy; TBXAS1 mutation screening is recommended
Guideline-Based Recommendations
Diagnosis
- Consider GHD in patients with predominant anemia and radiological bone anomalies or hard bone with non-aspirable marrow
- Perform genetic screening for TBXAS1 mutations in suspected inherited bone marrow failure syndromes
Management
- Use NSAIDs (aspirin or ibuprofen) as first-line therapy for GHD to improve anemia and thrombocytopenia
- Start with low-dose aspirin (75 mg/day) and escalate dose if hemoglobin response is inadequate
- Avoid corticosteroids due to frequent iatrogenic complications
Monitoring & Follow-up
- Monitor hemoglobin and platelet counts regularly to assess response
- Observe for treatment adherence and adjust NSAID dose accordingly
- Monitor inflammatory markers such as CRP as part of disease activity assessment
Risks
- NSAIDs at doses used showed no treatment-related adverse events in reported patients
- Corticosteroids carry risk of iatrogenic complications and should be avoided if possible
Patient & Prescribing Data
Eight patients aged 3.8 to 39 years with GHD and bone marrow failure
NSAID therapy led to transfusion independence and hematologic improvement within months; dose escalation may be necessary for some patients
Clinical Best Practices
- Include TBXAS1 gene in inherited bone marrow failure genetic panels
- Consider NSAIDs as a safer alternative to corticosteroids in GHD management
- Evaluate bone marrow biopsy and imaging findings to support diagnosis
- Ensure patient adherence to NSAID therapy for optimal outcomes
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
